Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(60 sites)
United States
UAB O'Neal Comprehensive Cancer Center - The Kirklin Clinic of UAB Hospital, Birmingham, Alabama City of Hope - Duarte Cancer Center, Duarte, California UCLA Health Bowyer Oncology Center, Los Angeles, California UCSF Helen Diller Medical Center at Parnassus Heights - Neurology, San Francisco, California Stanford University Medical Center - Neurology, Stanford, California